• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

重度抑郁症的精神药理学最新进展

Recent Advances in the Psychopharmacology of Major Depressive Disorder.

作者信息

Alexander Laith, Young Allan H

机构信息

Department of Psychological Medicine, School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

St Thomas' Hospital, London, UK.

出版信息

BJPsych Adv. 2023 Mar;29(2):117-130. doi: 10.1192/bja.2022.14. Epub 2022 Apr 4.

DOI:10.1192/bja.2022.14
PMID:39649121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7617086/
Abstract

This review highlights some of the recent advances in the psychopharmacology of Major Depressive Disorder (MDD). We synthesise evidence on emerging pharmacological therapies targeting the serotonergic system, before exploring several novel treatment targets: the glutamatergic system, the GABAergic system, and inflammation. When describing new treatment avenues, we examine the evidence base and how far these new treatments are from routine practice.

摘要

本综述重点介绍了重度抑郁症（MDD）心理药理学的一些最新进展。在探讨几个新的治疗靶点：谷氨酸能系统、γ-氨基丁酸能系统和炎症之前，我们综合了针对血清素能系统的新兴药物治疗的证据。在描述新的治疗途径时，我们审视了证据基础以及这些新治疗方法距离常规临床应用还有多远。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4844/7617086/a688aeec0459/EMS143728-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4844/7617086/b84803ca9ac6/EMS143728-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4844/7617086/b9a9371a1be0/EMS143728-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4844/7617086/7f3dca02a1ba/EMS143728-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4844/7617086/a688aeec0459/EMS143728-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4844/7617086/b84803ca9ac6/EMS143728-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4844/7617086/b9a9371a1be0/EMS143728-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4844/7617086/7f3dca02a1ba/EMS143728-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4844/7617086/a688aeec0459/EMS143728-f004.jpg

相似文献

1
Recent Advances in the Psychopharmacology of Major Depressive Disorder.重度抑郁症的精神药理学最新进展
BJPsych Adv. 2023 Mar;29(2):117-130. doi: 10.1192/bja.2022.14. Epub 2022 Apr 4.
2
Psychopharmacology Algorithms for Major Depressive Disorder: Current Status.精神药理学治疗重度抑郁症的算法：现状。
Adv Exp Med Biol. 2021;1305:429-445. doi: 10.1007/978-981-33-6044-0_21.
3
GABA System in Depression: Impact on Pathophysiology and Psychopharmacology.抑郁障碍中的 GABA 系统：对发病机制和精神药理学的影响。
Curr Med Chem. 2022;29(36):5710-5730. doi: 10.2174/0929867328666211115124149.
4
Keeping up with the clinical advances: depression.紧跟临床进展：抑郁症。
CNS Spectr. 2019 Aug;24(S1):25-37. doi: 10.1017/S1092852919001159.
5
The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences.内源性抑郁症的 Wistar-Kyoto 大鼠模型：一种探索治疗抵抗的工具，迫切需要关注性别差异。
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109908. doi: 10.1016/j.pnpbp.2020.109908. Epub 2020 Mar 4.
6
Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.重度抑郁症中γ-氨基丁酸神经传递的改变：支持证据及5-羟色胺能抗抑郁药影响的批判性综述
Drug Des Devel Ther. 2015 Jan 19;9:603-24. doi: 10.2147/DDDT.S62912. eCollection 2015.
7
Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments.大脑中的忧郁症：重度抑郁症的分子基础以及相关的药理学和非药理学治疗方法。
Genes (Basel). 2020 Sep 18;11(9):1089. doi: 10.3390/genes11091089.
8
Toll-like receptor 4: innate immune regulator of neuroimmune and neuroendocrine interactions in stress and major depressive disorder.Toll 样受体 4：应激和重度抑郁症中神经免疫和神经内分泌相互作用的先天免疫调节剂。
Front Neurosci. 2014 Sep 30;8:309. doi: 10.3389/fnins.2014.00309. eCollection 2014.
9
The future of psychopharmacology of depression.抑郁症的精神药理学的未来。
J Clin Psychiatry. 2010 Aug;71(8):971-5. doi: 10.4088/JCP.10m06223blu.
10
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.针对谷氨酸能系统治疗重度抑郁症：基本原理和迄今为止的进展。
Drugs. 2012 Jul 9;72(10):1313-33. doi: 10.2165/11633130-000000000-00000.

引用本文的文献

1
Psychedelic interventions for major depressive disorder in the elderly: Exploring novel therapies, promise and potential.老年重度抑郁症的迷幻剂干预：探索新疗法、前景与潜力。
Dialogues Clin Neurosci. 2025 Dec;27(1):98-111. doi: 10.1080/19585969.2025.2499458. Epub 2025 May 6.
2
A transdiagnostic systematic review and meta-analysis of ketamine's anxiolytic effects.一项关于氯胺酮抗焦虑作用的跨诊断系统评价和荟萃分析。
J Psychopharmacol. 2023 Aug;37(8):764-774. doi: 10.1177/02698811231161627. Epub 2023 Apr 2.

本文引用的文献

1
The anterior cingulate cortex as a key locus of ketamine's antidepressant action.前扣带皮层作为氯胺酮抗抑郁作用的关键部位。
Neurosci Biobehav Rev. 2021 Aug;127:531-554. doi: 10.1016/j.neubiorev.2021.05.003. Epub 2021 May 11.
2
Trial of Psilocybin versus Escitalopram for Depression.迷幻蘑菇与依地普仑治疗抑郁症的试验。
N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994.
3
Dose-response relationships of psilocybin-induced subjective experiences in humans.人类食用致幻蘑菇后主观体验的剂量-反应关系。
J Psychopharmacol. 2021 Apr;35(4):384-397. doi: 10.1177/0269881121992676. Epub 2021 Mar 4.
4
Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial.米诺环素增强治疗抵抗性抑郁症伴低度外周炎症患者的疗效：一项双盲随机临床试验结果。
Neuropsychopharmacology. 2021 Apr;46(5):939-948. doi: 10.1038/s41386-020-00948-6. Epub 2021 Jan 28.
5
Minocycline, but not doxycycline attenuates NMDA-induced [Ca2+]i and excitotoxicity.米诺环素而非多西环素可减轻 NMDA 诱导的 [Ca2+]i 升高和兴奋性毒性。
Neuroreport. 2021 Jan 6;32(1):38-43. doi: 10.1097/WNR.0000000000001558.
6
Ketamine: A tale of two enantiomers.氯胺酮：对映异构体的两面性。
J Psychopharmacol. 2021 Feb;35(2):109-123. doi: 10.1177/0269881120959644. Epub 2020 Nov 6.
7
Intravenous arketamine for treatment-resistant depression: open-label pilot study.静脉注射氯胺酮治疗难治性抑郁症：开放标签试点研究。
Eur Arch Psychiatry Clin Neurosci. 2021 Apr;271(3):577-582. doi: 10.1007/s00406-020-01110-5. Epub 2020 Feb 20.
8
Peripheral Blood Cell-Stratified Subgroups of Inflamed Depression.外周血细胞分层的炎症性抑郁症亚群。
Biol Psychiatry. 2020 Jul 15;88(2):185-196. doi: 10.1016/j.biopsych.2019.11.017. Epub 2019 Dec 2.
9
Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies.辅助鼻腔内给予氯胺酮治疗重性抑郁障碍：随机双盲对照安慰剂研究的系统评价。
J Affect Disord. 2020 Mar 15;265:63-70. doi: 10.1016/j.jad.2020.01.002. Epub 2020 Jan 3.
10
Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research.伏硫西汀用于改善重度抑郁症认知功能：从动物模型到临床研究
Front Psychiatry. 2019 Nov 6;10:771. doi: 10.3389/fpsyt.2019.00771. eCollection 2019.